Comparative Pharmacology
Head-to-head clinical analysis: KESIMPTA versus QAMZOVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KESIMPTA versus QAMZOVA.
KESIMPTA vs QAMZOVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KESIMPTA (ofatumumab) is a fully human anti-CD20 monoclonal antibody that selectively binds to the CD20 antigen on B lymphocytes, leading to B-cell lysis via complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). This results in depletion of circulating B cells, reducing inflammatory demyelination in multiple sclerosis.
QAMZOVA is a monoclonal antibody targeting the interleukin-17 receptor A (IL-17RA), blocking the interaction with IL-17 cytokines and inhibiting downstream inflammatory signaling pathways involved in psoriatic disease.
20 mg administered subcutaneously once monthly after a loading dose of 20 mg on Days 0, 7, and 14.
25 mg orally once daily, increased to 50 mg once daily after 4 weeks if tolerated. Maximum 100 mg once daily.
None Documented
None Documented
16 days (range 13–20 days) with linear pharmacokinetics; supports every 4-week dosing.
Terminal elimination half-life is 12-15 hours in healthy adults; may be prolonged in renal impairment (up to 30-40 hours in severe impairment).
Primarily degraded into small peptides and amino acids; not excreted renally or fecally as intact drug. Elimination pathways not fully characterized due to monoclonal antibody catabolism.
Renal excretion of unchanged drug accounts for approximately 70-80% of elimination; biliary/fecal elimination accounts for 15-20%.
Category C
Category C
Monoclonal Antibody, Anti-CD20
Monoclonal Antibody